Objective: Although preexposure prophylaxis with oral tenofovir (TFV) disoproxil fumarate/emtricitabine reduces HIV acquisition rates, poor adherence to and acceptability of daily vaginal gels have led to development of vaginal film formulations to improve adherence and, potentially, to enable episodic use.
INTRODUCTION
HIV infection remains a global health problem with sexual intercourse being the most common mode of transmission. Preexposure prophylaxis (PrEP) with tenofovir (TFV)-containing regimens has proven effective in randomized controlled trials using daily oral tenofovir/emtricitabine. Although effectiveness is best when product adherence is high, [1] [2] [3] [4] [5] poor adherence may result in no protection, especially in women. [6] [7] [8] Responding to the negative PrEP impact of poor adherence, alternatives to daily oral dosing have been pursued including sustained release products that provide long-term protection with infrequent dosing and topical products potentially suitable for either episodic or sustained use. [9] [10] [11] Topical PrEP efficacy has been demonstrated with vaginal gel and ring formulations of tenofovir and dapivirine, though these have been only modestly effective. 2, 7, 8, [12] [13] [14] It is hoped that, similar to contraceptive product development where multiple formulation options lead to increased adherence and efficacy across the population, alternative PrEP formulations will boost overall adherence. 15 On-demand microbicide products may be preferred for persons at risk of HIV infection who desire PrEP, but struggle with daily oral dosing, prefer to avoid the potential for longlasting toxicity from the systemic exposure of injectable formulations, or who only have occasional episodic HIV exposure risks not necessarily requiring long-term formulations. One such option in development is fast-dissolving vaginal film formulations of dapivirine and TFV, which, in gel and intravaginal ring formulations, have proven PrEP efficacy. 2, 7, 8, 12, 13, 16 Listerine breath mint strips are 1 example for fast-dissolving film formulations on the market. Among topical formulations, film may overcome limitations of the vaginal gel, which include messiness; frequent leakage from the vagina after application; and product storage and transport complications because of the bulkiness of the applicator. 17 By contrast, a vaginal film has less volume to leak from the vagina or dilute innate endogenous antimicrobial factors in vaginal fluid; much smaller size for discreteness of use and portability; and less packaging to dispose postapplication.
Vaginal films, such as the nonoxynol 9 contraceptive film, have proven more desirable than other dosage formulations, including gels, tablets, and even vaginal rings. [18] [19] [20] [21] Two previous studies have demonstrated the acceptability and pharmacokinetic (PK) equivalence of a fastdissolving dapivirine vaginal film. 22, 23 In this current study (FAME 05), we evaluated the single-dose, multicompartment pharmacokinetics [blood, cervical tissue (CT), cervicovaginal fluid (CVF), and rectal fluid (RF)] and pharmacodynamics (PD, ex vivo HIV tissue explant challenge) of a fastdissolving TFV film compared with the TFV 1% gel formulation used in previous clinical trials. A companion study, FAME 04, involved 1 week of daily dosing of the same TFV film and gel products with additional safety, immunological, and microbiome assessments. 24 
MATERIALS AND METHODS

Study Design and Participants
This was a 2-arm, single-site randomized cross-over study of 2 TFV formulations, conducted at the Drug Development Unit (DDU) of the Johns Hopkins Hospital in Baltimore, MD. The protocol was approved by the Johns Hopkins Medicine Institutional Review Board (IRB00046617) and registered with Clinicaltrials.gov (NCT02280109). Ten healthy, HIV-negative women between the ages of 18 and 45 years were recruited to participate. All participants provided informed consent before screening and study procedures. After a baseline evaluation to determine eligibility, each participant was randomized to one of the 2 sequences of a single vaginal dose of one of the 2 study products, either gel then film or film then gel. The study products were TFV 1% gel (a unit dose equivalent to 40 mg in 4 mL of gel) and tenofovir vaginal film (40 mg). The 2 by 2-inch TFV films were composed of hydroxypropyl methyl cellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, and glycerin. These products are not labeled for HIV prevention by Food and Drug Administration.
At the first study visit after qualification, the investigational product was applied by a gynecologist during a pelvic examination. The TFV gel was applied using a polyethylene vaginal applicator (HTI Plastics, Lincoln, NE). The TFV film was placed unfolded in the midvagina during a speculum examination. The participant remained recumbent for approximately 30 Participants were seen on day 14 for a safety evaluation. The second product was dosed during a similar point in a latter menstrual cycle (avoiding menses) followed by the same sampling schedule. A final set of cervical biopsies was collected at least 12 weeks before or after the second product dosing as negative control for the explant HIV challenge.
Clinical Assessment
Participants were assessed for adverse events (AEs) at each study visit. AEs were graded based on the Division of AIDS (DAIDS) 
Pharmacokinetic Sample Analysis
TFV in plasma, CVF, RF, and CT biopsy homogenate as well as TFV-DP concentrations in PBMC and CT homogenate were measured using ultraperformance liquid chromatographic tandem mass spectrometry (LC-MS/MS) that have been previously described. 25, 26 These methods were validated according to Food and Drug Administration Bioanalytical Method Validation Guidance. 27 The lower limits of assay quantifications (LLOQs) for these assays are as follows: plasma TFV 0.31 ng/mL, PBMC TFV-DP 50 fmol/sample or median 2 fmol/10 6 cells (based on number of cells analyzed), CVF TFV 0.625 ng/swab or median 0.005 ng/mg (based on swab weights), RF TFV 0.625 ng/swab or median 0.2 ng/mg (based on swab weights), CT TFV 0.05 ng/sample or median 0.003 ng/mg (based on biopsy weights), and CT TFV-DP 50 fmol/sample or median 3 fmol/mg (based on biopsy weights).
Pharmacodynamic Ex Vivo HIV Explant Challenge
As previously described, 2 CT biopsies were briefly exposed to HIV-1 BaL in the laboratory, and HIV infection was measured over the culture period by HIV-1 p24 ELISA assay (Alliance, Perkin Elmer) of culture supernatant (4, 7, 10, and 14 days after inoculation). 28, 29 The cumulative p24 antigen was calculated from the sum of all 4 p24 antigen supernatant concentrations for each biopsy, then divided by the original biopsy weight. The unit of analysis was this weight-adjusted cumulative p24 antigen averaged for each pair of biopsies, which was taken at each scheduled biopsy time.
Data Analysis
Concentration-time data and PK-PD relationships were visually examined (SigmaPlot, version 13; Systat Software, San Jose, CA). Noncompartmental analysis of concentration data estimated PK parameters including peak concentration (C max ), time to peak concentration (T max ), area under the concentration-time curve to last sample (AUC last ), and time to last concentration (T last ) (Phoenix WinNonlin version 6.4; Certara USA, Inc., Princeton, NJ). Readouts were summarized using nonparametric descriptive statistics (median and interquartile range), the Friedman test for comparisons among readouts, the Wilcoxon rank sum test for paired comparisons, and the Spearman test for correlations between matrix concentrations (IBM SPSS Statistics version 24, Armonk, NY). P values less than 0.05 were considered statistically significant. A PK-PD relationship was first assessed with linear regression of log-transformed TFV and TFV-DP concentrations in plasma and CT and CVF (each individually as single independent variables) with log-transformed cumulative p24 concentrations (dependent variable) (IBM SPSS). Iterative model fitting using an E max model (2-4 parameter Hill equation) with log-transformed PK and PD was performed to assess PK-PD relationships (Phoenix WinNonlin).
RESULTS
Subjects
Ten women were enrolled in the study, ranging in age from 22 to 45 years (median 33.5). Five women were selfidentified as African American, 4 as white (1 as Hispanic/ Latina), and 1 as Asian. All participants completed all study visits and evaluations.
Adverse Events
Of 22 AEs captured during the study, neither were serious nor were related to the study product (Table 1 ). All were resolved by the end of follow-up. Fourteen AEs occurred after gel dosing, whereas 7 occurred after film dosing (P = 0.20); 1 participant experienced an AE in the washout period between film and gel dosing.
Pharmacokinetics
After dosing of each product, plasma TFV concentrations reached a peak between 1 and 12 hours, and then fell to undetectable concentrations (,0.31 ng/mL) by 48 hours in all but 1 participant (film 0.39 ng/mL and gel 0.51 ng/mL) (Fig. 1) . T max occurred later after film dosing, median [interquartile range (IQR)] 8 hours (8, 8) , when compared with gel dosing, 4 (2, 8) (P = 0.02). TFV C max was higher in 9 of 10 participants after film dosing, when compared with gel dosing (Table 2 , P = 0.08). Plasma TFV concentration vs. time curves were similar before 8 hours, but separated (statistically significant) between 8 and 24 hours after dosing, during which time concentrations after film dosing continued to rise and were greater by 3.1-to 4.4-fold when compared with individually paired gel dosing (P , 0.02). Overall, plasma TFV noncompartmental C max and AUC last were higher after film than gel dosing (Table 2) . Finally, T last was later after film dosing, 24 hours (24, 24) , when compared with gel dosing, 18 hours (12, 24) (P = 0.06). PBMC TFV-DP concentrations were below limits of assay quantification in all samples tested.
CVF TFV concentrations sampled from all 3 intravaginal sites declined from 5 hours to 168 hours after dosing but remained detectable throughout the sampling interval (Fig. 2) . Only 1 of 10 participants had any CVF TFV concentration that was below the LLOQ 168 hours after dosing (exocervix, gel dosing). Midvagina CVF TFV C max 20) . Initial number indicates number of participants experiencing the AE; if multiple symptoms are included in a category, the number of participants affected by a particular symptom is indicated (unless only 1 participant was affected).
and AUC (both P = 0.014), as well as concentrations at all 3 sample times, were significantly higher after film compared with gel dosing (P # 0.02) ( Table 2 ). The differences ranged from 3.1-fold (2.0, 3.8) higher at 168 hours to 4.4-fold (2.9, 7.7) higher at 24 hours. Forniceal CVF TFV trended toward higher concentrations after film than gel at 5 hours (P = 0.08), but none of the exocervical CVF TFV concentrations differed between study products. When comparing among CVF sampling sites at any given time for the same product, forniceal samples were higher than exocervical samples, with a C max and AUC last forniceal: exocervical ratio of 2.0 (1.2, 6.9) and 2.0 (1.2, 6.8), respectively (both P # 0.01). Variability of samples (indicated by the range of quartiles) was also greater for film compared with gel. CVF concentrations between sites were highly correlated (rho . 0.94, P , 0.001).
TFV and TFV-DP concentrations in CT homogenates were also higher 5 hours after film dosing, 28 ng/mg (7, 52) and 160 fmol/mg (27, 485) , respectively, when compared with gel dosing (both P , 0.05). This resulted in paired film: gel ratios of 3.0 (1.1, 7.3) for TFV and 3.7 (2.0, 17.8) for TFV-DP (P # 0.04). Concentrations were not different 72 hours after dosing.
Using molar concentrations of TFV and TFV-DP, the combined (film and gel) TFV to TFV-DP ratio in CT was 532 (332, 999) and not different between products. At 5 hours after dosing when all matrices were available and detectable, combined (film and gel) CVF tenofovir concentrations were 2 log 10 and 5 log 10 greater than tissue and plasma concentrations, respectively (P , 0.001). CT TFV-DP correlated modestly with plasma TFV concentrations (rho = 0.522, P , 0.001) and correlated highly with both CVF (rho $ 0.818, P , 0.001) and CT (rho = 0.92, P , 0.001) concentrations.
Unlike TFV concentration and time differences (film greater than gel) at all other anatomic sites, RF TFV concentrations 5 hours after gel dosing were 12-fold (3, 39) greater than after film dosing (P = 0.004). The RF concentration distribution 5 hours after gel, 2.5 ng/mg (0.5, 26), overlapped the 5 hours CT homogenate TFV concentration for both film, 31 ng/mg (11, 63) , and gel, 9 ng/mg (6, 17) . RF T max values were more common at 5 hours, but higher concentrations were seen 72 hours after dose in 4 participants after film and 1 participant after gel. RF concentrations correlated least well with all other matrices (rho , 0.44, P . 0.01).
Pharmacodynamics (HIV-1 p24 Measurement)
Cumulative p24 antigen in the CT ex vivo HIV challenge assay was not different among values for baseline and both times (5 and 72 hours) for both film and gel formulations (P = 0.4) (Fig. 3) . Pairwise testing showed statistically significant differences only for the film formulation, which increased between the 5-and 72-hour sampling times (P , 0.01). Linear regression of cumulative P24 against Cmax units: TFV, plasma ng/mL, CVF ng/mg, RF ng/mg, CT ng/mg, and TFV-DP fmol/mg. AUC units: TFV, plasma ng-h/mL, CVF ng-h/mg, RF ng-h/mg, CT ng-h/mg, and TFV-DP fmol-h/mg. P values greater than 0.1 are not shown. *Comparison of plasma concentrations at 8, 12, and 24 hours are greater with film compared with gel (P , 0.02).
BLQ, below lower limits of assay quantitation.
drug concentrations (pooling concentrations for both film and gel dosing within each anatomic matrix) indicated no statistically significant PK-PD relationships (Fig. 4) . Excluding baselines, any imputed values, or both did not result in any statistically significant regression slopes. Similarly, sigmoid E max PK-PD modeling was not successful.
DISCUSSION
We demonstrated the feasibility of a single-dose TFV fast-dissolving film (40 mg) to achieve concentrations of TFV in plasma, CVF, and activated TFV-DP in CT, which exceed those after a single dose of TFV 1% gel during the day of dosing; both film and gel had similar concentrations 3 and 7 days later. Supported by the acceptability of the film established in the companion study, FAME 04, and the theoretical adherence advantages of films over other products, we believe that this study helps to advance TFV film as a potentially viable product for extended safety and efficacy testing as a topical microbicide.
In contrast to FAME 04, a 7-dose study of the same film and gel, we report greater concentrations in all matrices (at some time points) after film compared with gel dosing. Temporally richer FAME 05 sampling (2, 4, 5, 8, and 12 hours) could detect the later peaking and higher 8-to 24-hour plasma TFV differences with film, which indirectly indicate differences in CVF and tissue TFV. Complementarily, FAME 04 (with before dose and 2 hours after dose sampling) was more analytically rich with readouts beyond PK and larger sample size. The other study difference was that the film was folded in half before dosing in FAME 04, whereas in FAME 05, the film was not folded. Although folding may ease selfadministration, it can reduce the dissolution rate of the film in vitro; however, the effect of folding on clinical dissolution has not been evaluated (author's unpublished data).
In addition, our FAME 05 concentrations in all matrices were below those in FAME 04. For example, our CT TFV-DP was 40 fmol/mg (20, 93) and 169 fmol/mg (84, 506) 5 hours after gel and film dosing, respectively, whereas FAME 04 reported 222 fmol/mg (71, 556) and 937 fmol/mg (56, 1456) 2 hours after dosing gel and film, respectively. Accumulation of drug with the 7 daily doses in FAME 04 compared with the single dose in FAME 05 explains this difference. Vaginal tissue concentrations rise even higher with longer daily dosing-2000 fmol/mg (4 fmol/0.2 mL) after 2 weeks reported by Schwartz et al and 1807 fmol/mg (591, 5860) after 6 weeks in MTN-001, both of which studies dosed the same TFV 1% gel daily. 30, 31 Together, these studies indicate that the tissue accumulation continues through 2 weeks after which steady state is achieved. Continuing accumulation of tissue TFV-DP for weeks of dosing is expected based on every 24-hour dosing and a longer cervicovaginal tissue TFV-DP half-life, 53 hours (45, 68); accordingly, steady state (6 half-lives) would require (IQR) 11-17 days, consistent with the similarity in 2-week Schwartz et al and 6 week MTN-001 reports. [30] [31] [32] Five hours after a single TFV film dose, CT TFV-DP concentrations easily exceeded vaginal tissue TFV-DP concentrations associated with daily oral TDF dosing [estimated from combined MTN-001 and HPTN 066, 23 fmol/mg (17, 25) ], which takes weeks to achieve after commencing daily oral dosing. 31, 33 The CVF concentrations far exceeded CVF concentrations (.1000 ng/mL or ;1 ng/mg) reported in CAPRISA 004 to be associated with 75% relative risk reduction in a post hoc analysis. 14 Finally, a single dose of the TFV film achieved similar CVF TFV concentrations achieved with single and multiple doses of TFV 1% vaginal gel in several previous studies, including in the subset of CAPRISA 004 women who dosed within 1 day of a CVF sampling visit. 14, 30, 31 Given these favorable concentration comparisons and the high levels of HIV protection achievable when adherence is high for both oral and topical dosing, this evidence recommends advancing the film formulation for further clinical development.
Development of the TFV film for use as a single episodic dose before HIV exposure might be considered but depends on several key unknowns, namely, whether cervicovaginal tissue concentration of active drug is the single critical variable associated with PrEP efficacy, whether tissue concentrations associated with oral dosing are appropriate concentration targets, and how long the concentration needs to be maintained.
Protective tissue TFV-DP concentrations may be different with oral dosing compared with topical dosing, but no quantitative assessment based on clinical data is available to quantify the difference if it exists. This potential difference may be due to the addition of FTC to oral TDF dosing in the fixed dose combination; however, Partners PrEP failed to demonstrate a statistically significant difference between oral TDF alone and oral TDF/FTC in the only study to directly address this. Other variables (eg, undetermined frequency of anal sex, lack of systemic concentrations as backup to topical dosing) have been suggested to explain less anticipated vaginal antiretroviral protection, but none of these explanations have been proven contributory, much less are there quantitative estimates of their relative contributions, if any.
The evidence for the association between cervicovaginal fluid or tissue concentration and PrEP efficacy relies on post hoc analyses. In an analysis of seroconversion rates across the 6 primary daily dosing PrEP efficacy randomized clinical trials, using oral vs. vaginal tissue TFV-DP concentration-based differences provided a much tighter sigmoid E max PK-PD model fit than systemic drug concentrations alone. 1, [3] [4] [5] [6] [7] 34 Possibly arguing against this, adherence adjustments in 3 TFV vaginal gel trials (CAPRISA 004, FACTS 001, VOICE) all demonstrated improved 60%-75% protection in post hoc analyses, 2, 7, 8, 12, 14 despite estimates of higher tissue TFV-DP concentrations compared with oral dosing (discussed above). Furthermore, these PK-guided adherence adjustments were dichotomous adjustments into adherent and poorly adherent cohorts and lacked quantitative adherence benchmarks (similar to STRAND and HPTN 066 for oral dosing) to fairly judge efficacy in highly adherent women. 33, 35 Finally, it remains unclear how long protective concentrations must be sustained after HIV exposure. Although film achieves tissue TFV-DP concentrations in 5 hours that are 7-fold greater than estimated steady-state tissue concentrations associated with 90% protection in Partners PrEP (see below), the tissue TFV-DP concentration falls to 40% of the clinical tissue IC 90 by 72 hours after the single dose and may need additional doses for protection in the episodic dosing setting.
In a post hoc analysis of CAPRISA 004, CVF concentrations of .100 ng/mL and .1000 ng/mL were associated with 65% and 76% protection, respectively, thus, demonstrating a concentration response. Using these CVF concentrations as efficacy targets, however, is challenging because of the episodic dosing of gel in CAPRISA 004 wherein CVF samples were collected days or weeks after the dose, resulting in concentrations at the time of sampling that were 1000-10,000 times lower than the likely concentration at the time of the HIV exposure (;100,000 ng/mL or ;1000 ng/mg). 14 Despite uncertainty as to the CVF or tissue concentration target providing protection at the time of exposure, that the film achieves concentrations exceeding those of the gel and post hoc analyses indicating gel efficacy at least as high as 76% with episodic use, supports further development of the film.
Because of the absence of clinical trial data to clearly indicate the TFV-DP concentration, anatomic site, and duration best-predicting efficacy, viral challenge in animal models and ex vivo human tissue explants have been used as surrogates. Macaque models repeatedly demonstrate protection from simian-human immunodeficiency (SHIV) and simian immunodeficiency virus (SIV) vaginal challenge with previous TFV dosing. [36] [37] [38] [39] [40] We used the explant challenge in FAME 05 but failed to demonstrate an antiviral effect. By contrast, FAME 04 demonstrated an antiviral effect with CT TFV-DP IC 90 of 813 fmol/mg. The difference in explant results may largely be explained by the fact that all, but 1, of the single-dose FAME 05 CT concentrations fell well below the explant IC 90 in multipledose FAME 04. Accordingly, there were too few high concentrations to generate a statistically significant downward slope.
As with selecting tissue concentration targets, interpreting explant challenge model IC 90 results do not map directly to a clinical IC 90 . Consider, in MTN-001, participants demonstrated high adherence to prescribed daily TDF (indicated by median before dose TFV serum concentration of 65 ng/mL), yet the vaginal tissue homogenate TFV-DP concentrations were below 25 fmol/mg. 31 With similar predose serum TFV concentrations in 1 high adherence Partners PrEP cohort, .40 ng/mL serum TFV, the tissue TFV-DP concentrations are very likely similar. 41 This high adherence Partners PrEP subgroup had relative risk reduction of 89% for TDF only and 91% for TDF/FTC, approximating a clinical IC 90 41 (This assumes no sex differences in efficacy that Partners PrEP was not powered to detect). By comparison, the explant IC 90 reported in FAME 04 is at least 1.5 log 10 greater than the clinical IC 90 from Partners estimated above. Similarly, the colon tissue explant IC 90 , 10,233 fmol/ mg (RMP-02/MTN-006), is 1.7-2.5 log 10 greater than the clinical IC 90 for colon tissue TFV-DP estimated in iPrEx 1, 35, 42, 43 (The iPrEx clinical IC 90 is based on 90% efficacy associated with 2-4 doses per week based on the STRAND study; in HPTN 066, 2-4 doses per week achieved colon tissue homogenate TFV-DP concentrations from 27-186 fmol/mg. 1, 33, 35 ). Accordingly, both the cervicovaginal and colon explant challenge models seem too stringent and need recalibration to estimate the likelihood of clinical protection. In addition, as discussed above, whether the calibration for oral TDF (often complicated by concomitant dosing with emtricitabine) is relevant for topical TFV remains to be demonstrated and will require an efficacy trial.
Concluding, we demonstrated that a single dose of TFV 40-mg film achieved higher and more sustained concentrations in plasma, CVF, and CT compared with TFV 1% (40 mg) gel. Furthermore, CT TFV-DP and CVF TFV concentrations exceed concentrations associated with high levels of protection with oral and vaginal dosing, respectively. With its single-dose advantages compared with TFV gel, and several theoretical advantages of films over gels, which may favorably impact adherence, the film formulation remains a promising vaginal microbicide candidate as an alternative to oral PrEP. Longer duration safety and efficacy studies are needed to establish the anticipated adherence advantage and, possibly, superior efficacy of the TFV film formulation relative to gel or oral PrEP.
